Paper Details

  1. Home
  2. Paper Details

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.

Author: AlosaimySara, BargerMelissa, BouchardJeannette, ButtSaira, CabanillaM Gabriela, CiminoChristo L, CohenKeira A, El GhaliAmer, FiskeChristina T, FrensJeremy J, GoreTristan W, HamadYasir, HasbunRodrigo, HolgerDana J, HowardCatessa, KaipEmily A, LucasKristen, MammadovaMehriban, Mejia-ChewCarlos, MolinaKyle C, MorrisetteTaylor, OngAaron, PhilleyJulie V, RybakMichael J, SimonyanAnahit, StevensRyan W, ThomasMichael, Tupayachi-OrtizMaria G, UmanaVirginia E, VemulaRaaga, WadleCarly, WebbAndrew J, ZeuliJohn D

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This multicenter retrospective study examined the long-term clinical success, safety, and tolerability of omadacycline (OMC) for nontuberculous mycobacteria (NTM) infections. Seventy-five patients were included in the analysis. Three-month clinical success was observed in 80.0% of patients, and adverse events attributable to OMC occurred in 32.0% of patients, leading to drug discontinuation in 9.3% of patients.
Paper Details　
Original Abstract of the Article :
Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including <i>Mycobacteroides abscess...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583686/

データ提供：米国国立医学図書館（NLM）

Omadacycline: A New Frontier in Nontuberculous Mycobacteria Infections

Nontuberculous mycobacteria (NTM) infections are on the rise, posing a significant challenge in the world of infectious diseases. It's like a desert oasis teeming with unexpected dangers. This research delves into the long-term efficacy and safety of omadacycline (OMC), a novel antibiotic, in treating NTM infections. The study analyzed data from a large multicenter cohort of patients with NTM infections, examining the effectiveness of OMC over a period of three months to one year.

A Promise of Success in the Desert of NTM Infections

The study found that OMC demonstrated promising results in treating NTM infections, achieving clinical success in 80% of patients within three months. This is like finding a hidden spring in the desert oasis, providing a source of relief and recovery. The researchers also observed that OMC was well tolerated, with adverse effects reported in only 32% of patients. This finding suggests that OMC could be a valuable tool for managing NTM infections, potentially changing the landscape of treatment options.

A New Oasis in the Desert of NTM Infections

This research offers a beacon of hope for patients battling NTM infections. The study suggests that OMC could be a safe and effective treatment option, potentially improving patient outcomes. It's like discovering a new oasis in the desert, providing a haven of healing and recovery. While more research is needed to fully assess the long-term benefits of OMC, this study offers a promising glimpse into the future of NTM infection management.

Dr. Camel's Conclusion

This study highlights the potential of OMC as a promising treatment for NTM infections. This discovery offers a ray of hope in the challenging landscape of infectious diseases, much like finding a hidden oasis in a vast and unforgiving desert. This research could lead to improved outcomes for patients battling NTM infections, paving the way for a more hopeful future.

Date :
  1. Date Completed 2023-10-23
  2. Date Revised 2023-10-23
Further Info :

Pubmed ID

37768312

DOI: Digital Object Identifier

PMC10583686

Related Literature

Article Analysis
・Effects of omadacycline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.